Tau Protein Dynamics in Neurodegenerative Disease Mechanisms

The tau protein is a neuronal microtubule‐associated protein that fulfils critical roles in stabilising axonal transport, maintaining cytoskeletal integrity and modulating synaptic function. In health, tau adopts dynamic conformations regulated by a balance of phosphorylation, alternative splicing and interactions with other biomolecules. In disease, aberrant post-translational modifications and conformational shifts drive tau self-association into oligomers and fibrils, ultimately forming neurofibrillary tangles characteristic of Alzheimer’s disease and related tauopathies. Recent work has revealed that tau can undergo liquid–liquid phase separation to form biomolecular condensates at synapses and in the cytoplasm, providing a new paradigm for how tau clusters might nucleate pathological assemblies. Genetic and chemical factors, including polyanions and familial mutations, modulate the equilibrium between inert monomers and seed-competent species, influencing the rate of amyloidogenesis and the structure of resulting aggregates. Tau aggregates disrupt neuronal function through microtubule destabilisation, impaired axonal transport, nuclear dysfunction and activation of cell-cycle dysregulation pathways. Understanding the interplay of tau’s structural polymorphism, its capacity to form oligomeric seeds and the cellular factors that govern these transitions is essential for the development of disease-modifying therapies that target early, pre-fibrillar stages of pathology.

Research from Nature Portfolio

Recent studies have shown that tau can form nanoscale biomolecular condensates in presynaptic terminals via activity-dependent liquid–liquid phase separation. These condensates selectively regulate the clustering and mobility of recycling synaptic vesicles, suggesting a physiological role for tau in neurotransmission and a possible route by which dysregulated condensate formation seeds pathological aggregation. A foundational mechanistic model has been established by single-molecule fluorescence analysis of tau repeat domains, revealing that aggregation proceeds through monomeric assembly into small oligomers followed by a slow structural conversion before fibril formation. This kinetic framework quantifies how disease-linked mutations alter the energy landscape of tau assembly and highlights oligomeric intermediates as potential therapeutic targets to arrest amyloidogenesis at its earliest stages.

Tau Protein Dynamics in Neurodegenerative Disease Mechanisms publication trend

The graph below shows the total number of articles in tau protein dynamics in neurodegenerative disease mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Liquid–liquid phase separation: A physicochemical process by which soluble proteins demix into concentrated condensates without membranes.

Biomolecular condensates: Dynamic, non‐membrane‐bound assemblies of proteins and nucleic acids formed by phase separation.

Amyloidogenesis: The multistep process leading from soluble protein monomers to insoluble, fibrillar amyloid aggregates.

Oligomer: A small, non-fibrillar assembly of protein monomers often implicated as a toxic intermediate in aggregation pathways.

Polyanion: A negatively charged polymer or biomolecule that can interact electrostatically with positively charged protein regions to influence aggregation.

Seed-competent species: Aggregated or conformationally altered protein forms capable of templating the conversion of native monomers into pathological assemblies.

References

1. Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer’s disease related proteins. Molecular Neurodegeneration (2023).
2. Tau forms synaptic nano-biomolecular condensates controlling the dynamic clustering of recycling synaptic vesicles. Nature Communications (2023).
3. Expanded Conformations of Monomeric Tau Initiate Its Amyloidogenesis**. Angewandte Chemie International Edition (2023).
4. Chemical Features of Polyanions Modulate Tau Aggregation and Conformational States. Journal of the American Chemical Society (2023).
5. A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nature Communications (2015).
6. Inert and seed-competent tau monomers suggest structural origins of aggregation. eLife (2018).